Specialty Pharma Journal Specialty, Precision & Technology
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2018 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and United Therapeutics Corporation (Nasdaq: UTHR) today announced that the companies have entered into a global license agreement for Arena’s Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of …
Tag Archives: PAH
November, 2018
October, 2018
-
3 October
Arena Announces Positive Long-Term Data from its Phase 2 Trial for Ralinepag in Pulmonary Arterial Hypertension
SAN DIEGO, Oct. 2, 2018 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive data from a planned interim analysis of the ongoing open-label extension of the Phase 2 trial of its investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the …
September, 2018
-
19 September
Actelion’s Opsumit Significantly Improved Pulmonary Vascular Resistance in First Trial in Portopulmonary Hypertension
ALLSCHWIL, Switzerland–(BUSINESS WIRE)–Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced the results of the first randomized controlled trial in portopulmonary hypertension (PoPH), which showed OPSUMIT® (macitentan) significantly improved pulmonary vascular resistance (PVR) compared with placebo, meeting the primary endpoint of the study. Presented as …
August, 2018
-
30 August
Arena Presents Positive Phase 1 Clinical Data for its Investigational Pulmonary Arterial Hypertension Drug
SAN DIEGO, Aug. 28, 2018 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq : ARNA ) today announced that data from two Phase 1 clinical studies evaluating an extended-release (XR) formulation of its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of …
January, 2018
-
3 January
Corsair Pharma and United Therapeutics Collaborate to Advance Novel Treprostinil Prodrugs
SOUTH SAN FRANCISCO, Calif. and SILVER SPRING, Md., Jan. 3, 2018 /PRNewswire/ — United Therapeutics Corporation (NASDAQ: UTHR), a leading biotechnology company focused on development of therapies for the treatment of pulmonary arterial hypertension (PAH), and Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced …
September, 2017
-
20 September
Acceleron Amends Agreement with Celgene, Taking Back Rights to PAH Candidate Sotatercept
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it has amended the sotatercept development and commercialization collaboration agreement with Celgene Corporation, originally executed on February 20, 2008. The amended agreement provides Acceleron …
July, 2017
-
12 July
Arena Pharmaceuticals’ Ralinepag Demonstrates Positive Results in Mid-Stage PAH Study
SAN DIEGO, July 10, 2017 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced positive Phase 2 results for ralinepag, an investigational, long-acting, orally administered prostacyclin receptor agonist under development for the treatment of pulmonary arterial hypertension (PAH). In this 61-patient study, the primary efficacy analysis demonstrated a statistically significant absolute change from baseline in …
June, 2017
-
16 June
J&J Completes Acquisition of Actelion, Which Launches Actelion Spin-Off Idorsia
NEW BRUNSWICK, N.J. – June 16, 2017 – Johnson & Johnson (NYSE:JNJ) today announced the completion of the acquisition of Actelion Ltd for a total purchase price of approximately $30 billion in cash. The acquisition was completed through an all-cash public tender offer by Johnson & Johnson’s Swiss subsidiary, Janssen …
October, 2016
-
21 October
Gilead Discontinues PAH and DKD Tests After Mid-Stage Failure; Advances NASH Treatment into Phase III Trials
FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. 20, 2016– Gilead Sciences, Inc.(Nasdaq:GILD) today announced the top-line results from three Phase 2 studies of GS-4997 (selonsertib), an investigational inhibitor of apoptosis signal-regulating kinase 1 (ASK1), in nonalcoholic steatohepatitis (NASH), pulmonary arterial hypertension (PAH) and diabetic kidney disease (DKD). GS-4997 demonstrated anti-fibrotic activity in an …
March, 2016
-
21 March
BioMarin’s PKU Drug Demonstrates Mixed Results in Late-Stage Study
SAN RAFAEL, Calif., March 21, 2016 (GLOBE NEWSWIRE) — BioMarin announced today that the pivotal Phase 3 PRISM-2 study (formerly referred to as 165-302) of pegvaliase met the primary endpoint of change in blood Phe compared with placebo (p<0.0001) in preliminary results. During the 8 week PRISM-2 double-blind, placebo-controlled, randomized …